International Thyroid Cancer Survivors' Conference Brings Together Survivors, Caregivers, and Expert Speakers in Chicago, October 19-21
02 oct. 2018 10h01 HE
|
ThyCa
CHICAGO, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ThyCa: Thyroid Cancer Survivors' Association, Inc., has secured an impressive lineup of more than 35 expert speakers for the 21st International Thyroid...
Interpace Diagnostics Announces CIGNA’s Expansion of Coverage to Now Include ThyraMIR®
26 juil. 2018 08h37 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...
Interpace Diagnostics Group Reports First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
15 mai 2018 08h00 HE
|
Interpace Diagnostics Group, Inc.
Revenue Grew 39% Over the Prior Year’s Quarter and 10% Over the Prior Period Record Quarterly Revenue of $4.8 Million and Record Quarterly Cash Receipts of $4.4 Million Cash & Cash Equivalents...
Interpace Diagnostics Announces Launch of New Thyroid Test
14 mai 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
BOSTON, May 14, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results, Business Progress and Recent Accomplishments on Tuesday, May 15, 2018
11 mai 2018 09h10 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., May 11, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...
Interpace Diagnostics Announces Expanded Coverage Among Blue Cross Blue Shield Plans
10 mai 2018 09h00 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that...
Interpace Diagnostics Enters Agreement with One of the Largest, Integrated Health Systems in the US
18 avr. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides...
Carcinoembryonic Antigen Market to hit $2.7bn by 2023: Global Market Insights, Inc.
20 avr. 2017 06h30 HE
|
Global Market Insights, Inc
Ocean View, Delaware, April 20, 2017 (GLOBE NEWSWIRE) -- The research report “Carcinoembryonic Antigen (CEA) Market Size By Application (Colorectal, Pancreatic, Ovarian, Breast, Thyroid Cancer),...
Fertility Drugs Increase Thyroid Cancer Risk
09 oct. 2009 14h52 HE
|
Larry and Belinda Wurn
GAINESVILLE, FL--(Marketwire - October 9, 2009) - Women who take the most common fertility
drugs, progesterone and clomiphene, are at a greater risk to develop
thyroid cancer than those who don't,...
PenCol Compounding Pharmacy Has Solution for Armour(R) Thyroid Backorder
14 sept. 2009 16h02 HE
|
PenCol Compounding Pharmacy
DENVER, CO--(Marketwire - September 14, 2009) - Forest Laboratories, Inc., the maker of the
widely used hormone therapy drug, Armour® Thyroid, recently announced
it has placed the medication on...